Recently, CASPR2 antibody-associated encephalitis was presented as a subentity of encephalitis with antibodies against the voltage-gated potassium channel (VGKC) complex. Besides limbic encephalitis, CASPR2 antibodies are also found in Isaac syndrome and Morvan syndrome. 1, 2 The specific underlying pathogenic mechanisms in limbic encephalitis are unknown. Our data suggest an antibody-and complement-mediated pathology in CASPR2 antibody-associated encephalitis.
Since 2010, our 62-year-old male patient has had unrecognized dyscognitive seizures and acoustic hallucinations. In 2012, a loss of short-term memory was also noticed. EEG and MRI conducted in August 2012 were normal (figure, A). In January 2013, his symptoms worsened and he was admitted to a hospital. At this time, MRI examination showed volume and T2/fluid-attenuated inversion recovery (FLAIR) signal increase in the right hippocampus and amygdala (figure, A).
Due to suspicion of a malignant process, the right hippocampus and parts of the temporal lobe, including the amygdala, were resected. Neuropathologic investigations ruled out tumor formation. Detailed evaluation, however, showed moderate parenchymal presence of CD3 1 and CD8 1 T lymphocytes (figure, C). The lack of these cells in apposition to neurons suggests the absence of T cell-mediated neuronal destruction. CD68 staining showed mild activation of microglial cells ( figure, D) . Furthermore, CD20 and CD138 immunostaining showed small numbers of B cells (figure, E) and plasma cells (figure, F), predominantly in the perivascular space of blood vessels. Immunoglobulin (Ig) staining showed a strong leakage of Ig through the blood-brain barrier. In areas with less blood-brain barrier leakage, however, some deposition of Ig on the membranes of neurons could be detected (figure, G). In these areas some neurons showed shrinkage and nuclear changes, suggesting degeneration (figure, G). Degenerating neurons were absent in the amygdala ( figure, H) , but the hippocampus revealed few degenerating neurons ( figure, I ). Complement deposition, like in hippocampi of other patients with VGKC-complex encephalitis, 3 was detected in a few neurons (figure, J and K). Such deposition was not found in the cortex or hippocampi of NMDAR2, Hu2, Ma22, or GAD encephalitis patients, patients with mesial temporal lobe epilepsy with hippocampal sclerosis or Alzheimer disease, or normal controls. 3 In March 2013, VGKC-complex antibodyassociated encephalitis was diagnosed and methylprednisolone (MP) treatment was started (IV followed by oral administration). This resulted in a remarkable improvement of short-term memory. To detect a potential underlying malignancy, we then performed a whole-body fluorodeoxyglucose PET, which was negative. In July 2013, 2 months after the last MP IV treatment, the patient's short-term memory problems again worsened, while attentional deficits fluctuated. MRI scans now showed a progressive cortical and hippocampal atrophy (figure, A). At this time, serum and CSF were analyzed again and were found to be positive for CASPR2 antibodies (serum and CSF obtained in April, titers 1:32,000 and 1:128, respectively, see panel B of the figure). There were no antibodies to LGI1, NMDAR, GAD65, GABA B receptors, AMPA receptors type 1 and type 2, or glycine receptors.
The antibody index (AI, i.e., the ratio between the CSF/serum quotients of CASPR2 antibody titers and total IgG concentrations) determines whether antibodies are formed intrathecally. We considered an AI .4 as an indication of intrathecal production of the specific antibody. This conservative cutoff was used because any lower cutoff may give false positive results when titers are used. 3 The values were as follows: April 2013: AI 5 1.1; July: AI 5 1.0; and October: AI 5 2.5. Therefore, CASPR2 antibodies were produced mainly peripherally.
In July 2013, in addition to oral prednisolone, monthly cyclophosphamide infusions (15 mg/kg body weight) were started ( figure, A) . Thereafter, CASPR2 antibodies decreased ( figure, B) , neuropsychological deficits vanished, and the patient's condition stabilized. Further CSF analysis showed no pleocytosis or intrathecal IgG synthesis. MRI showed a discrete FLAIR intense signal in the left hippocampus but no further progression of global atrophy ( figure, A) . We had no indications for neuromyotonia or myasthenia gravis as CASPR2-associated symptoms at any time.
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